Questions regarding the safety and duration of immunity following live yellow fever vaccination

Ian J. Amanna, Mark Slifka

    Research output: Contribution to journalReview article

    11 Citations (Scopus)

    Abstract

    Introduction: The World Health Organization (WHO) and other health agencies have concluded that yellow fever booster vaccination is unnecessary since a single dose of vaccine confers lifelong immunity. Areas covered: We reviewed the clinical studies cited by health authorities in their investigation of both the safety profile and duration of immunity for the YFV-17D vaccine and examined the position that booster vaccination is no longer needed. We found that antiviral immunity may be lost in 1-in-3 to 1-in-5 individuals within 5 to 10 years after a single vaccination and that children may be at greater risk for primary vaccine failure. The safety profile of YFV-17D was compared to other licensed vaccines including oral polio vaccine (OPV) and the rotavirus vaccine, RotaShield, which have subsequently been withdrawn from the US and world market, respectively. Expert commentary: Based on these results and recent epidemiological data on vaccine failures (particularly evident at >10 years after vaccination), we believe that current recommendations to no longer administer YFV-17D booster vaccination be carefully re-evaluated, and that further development of safer vaccine approaches should be considered.

    Original languageEnglish (US)
    Pages (from-to)1519-1533
    Number of pages15
    JournalExpert Review of Vaccines
    Volume15
    Issue number12
    DOIs
    StatePublished - Dec 1 2016

    Fingerprint

    Yellow Fever
    Immunity
    Vaccination
    Vaccines
    Safety
    Rotavirus Vaccines
    Health
    Poliomyelitis
    Antiviral Agents

    Keywords

    • antibody duration
    • flaviviruses
    • immunity
    • neurotropic
    • vaccination
    • viscerotropic
    • Yellow fever virus

    ASJC Scopus subject areas

    • Immunology
    • Molecular Medicine
    • Pharmacology
    • Drug Discovery

    Cite this

    Questions regarding the safety and duration of immunity following live yellow fever vaccination. / Amanna, Ian J.; Slifka, Mark.

    In: Expert Review of Vaccines, Vol. 15, No. 12, 01.12.2016, p. 1519-1533.

    Research output: Contribution to journalReview article

    @article{435d8004dda8437aa060dbd00c9393a4,
    title = "Questions regarding the safety and duration of immunity following live yellow fever vaccination",
    abstract = "Introduction: The World Health Organization (WHO) and other health agencies have concluded that yellow fever booster vaccination is unnecessary since a single dose of vaccine confers lifelong immunity. Areas covered: We reviewed the clinical studies cited by health authorities in their investigation of both the safety profile and duration of immunity for the YFV-17D vaccine and examined the position that booster vaccination is no longer needed. We found that antiviral immunity may be lost in 1-in-3 to 1-in-5 individuals within 5 to 10 years after a single vaccination and that children may be at greater risk for primary vaccine failure. The safety profile of YFV-17D was compared to other licensed vaccines including oral polio vaccine (OPV) and the rotavirus vaccine, RotaShield, which have subsequently been withdrawn from the US and world market, respectively. Expert commentary: Based on these results and recent epidemiological data on vaccine failures (particularly evident at >10 years after vaccination), we believe that current recommendations to no longer administer YFV-17D booster vaccination be carefully re-evaluated, and that further development of safer vaccine approaches should be considered.",
    keywords = "antibody duration, flaviviruses, immunity, neurotropic, vaccination, viscerotropic, Yellow fever virus",
    author = "Amanna, {Ian J.} and Mark Slifka",
    year = "2016",
    month = "12",
    day = "1",
    doi = "10.1080/14760584.2016.1198259",
    language = "English (US)",
    volume = "15",
    pages = "1519--1533",
    journal = "Expert Review of Vaccines",
    issn = "1476-0584",
    publisher = "Expert Reviews Ltd.",
    number = "12",

    }

    TY - JOUR

    T1 - Questions regarding the safety and duration of immunity following live yellow fever vaccination

    AU - Amanna, Ian J.

    AU - Slifka, Mark

    PY - 2016/12/1

    Y1 - 2016/12/1

    N2 - Introduction: The World Health Organization (WHO) and other health agencies have concluded that yellow fever booster vaccination is unnecessary since a single dose of vaccine confers lifelong immunity. Areas covered: We reviewed the clinical studies cited by health authorities in their investigation of both the safety profile and duration of immunity for the YFV-17D vaccine and examined the position that booster vaccination is no longer needed. We found that antiviral immunity may be lost in 1-in-3 to 1-in-5 individuals within 5 to 10 years after a single vaccination and that children may be at greater risk for primary vaccine failure. The safety profile of YFV-17D was compared to other licensed vaccines including oral polio vaccine (OPV) and the rotavirus vaccine, RotaShield, which have subsequently been withdrawn from the US and world market, respectively. Expert commentary: Based on these results and recent epidemiological data on vaccine failures (particularly evident at >10 years after vaccination), we believe that current recommendations to no longer administer YFV-17D booster vaccination be carefully re-evaluated, and that further development of safer vaccine approaches should be considered.

    AB - Introduction: The World Health Organization (WHO) and other health agencies have concluded that yellow fever booster vaccination is unnecessary since a single dose of vaccine confers lifelong immunity. Areas covered: We reviewed the clinical studies cited by health authorities in their investigation of both the safety profile and duration of immunity for the YFV-17D vaccine and examined the position that booster vaccination is no longer needed. We found that antiviral immunity may be lost in 1-in-3 to 1-in-5 individuals within 5 to 10 years after a single vaccination and that children may be at greater risk for primary vaccine failure. The safety profile of YFV-17D was compared to other licensed vaccines including oral polio vaccine (OPV) and the rotavirus vaccine, RotaShield, which have subsequently been withdrawn from the US and world market, respectively. Expert commentary: Based on these results and recent epidemiological data on vaccine failures (particularly evident at >10 years after vaccination), we believe that current recommendations to no longer administer YFV-17D booster vaccination be carefully re-evaluated, and that further development of safer vaccine approaches should be considered.

    KW - antibody duration

    KW - flaviviruses

    KW - immunity

    KW - neurotropic

    KW - vaccination

    KW - viscerotropic

    KW - Yellow fever virus

    UR - http://www.scopus.com/inward/record.url?scp=84996560239&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84996560239&partnerID=8YFLogxK

    U2 - 10.1080/14760584.2016.1198259

    DO - 10.1080/14760584.2016.1198259

    M3 - Review article

    C2 - 27267203

    AN - SCOPUS:84996560239

    VL - 15

    SP - 1519

    EP - 1533

    JO - Expert Review of Vaccines

    JF - Expert Review of Vaccines

    SN - 1476-0584

    IS - 12

    ER -